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What is already known on this topic?
Hepatitis delta virus (HDV) is a rare viral infection of the liver with poten-
tially life-threatening consequences. Because of the rarity of the disease
and a general lack of awareness, many patients may have gaps in critical
disease-specific knowledge.
What is added by this report?
Little is known about the experiences of patients living with HDV. This qual-
itative study may be among the first to examine experiences of patients liv-
ing with HDV and their caregivers to assess this population’s unique needs
and challenges to care.
What are the implications for public health practice?
Identifying challenges to care and needs of HDV patients and their care-
givers may help improve provider and public health practitioners’ ability to
educate and care for this population.
Abstract
Introduction
Hepatitis delta virus (HDV) is a serious coinfection of the hepatit-
is B virus (HBV) that is estimated to affect between 48 to 72 mil-
lion people worldwide. Data are limited on the informational
needs of people living with HDV. The Hepatitis B Foundation, a
US-based nonprofit organization that provides support to people
living with HBV and HDV, receives emails (queries) as part of a
helpline, a service to provide information, resources, and support
to people affected by HBV and HDV.
Methods
Query content was analyzed to assess the impact of HDV at the in-
dividual level. A total of 65 HDV-related queries from 17 coun-
tries were received from October 2016 to January 2019, and all
were analyzed for this study.
Results
Thematic analysis of queries indicated 4 dominant themes. Three
were related to a need for information about 1) the disease and
prevention of it, 2) disease symptoms and outcomes, and 3) treat-
ment options. The fourth theme was related to barriers and quality
of life. Individuals requested information on treatment options,
medication access, diagnostic test interpretation, and clinical trials.
Conclusion
Our study highlights the needs and lived experience of patients
with HDV and summarizes critical information gaps. Findings can
inform health care providers, public health professionals, and the
pharmaceutical and biotechnology industries about the informa-
tional needs and lived experiences of individuals living with HDV
and help create future HDV-related educational resources, care,
and clinical trials.
Introduction
Viral hepatitis accounts for an estimated 1.34 million deaths
worldwide per year. Since 1990, viral hepatitis mortality has in-
creased by 63%, and in 2017, hepatitis was the seventh leading
cause of death in the world (1–4). Hepatitis delta virus (HDV) is a
serious coinfection of HBV that is estimated to affect between 48
and 72 million people (13%–14.5%) (5–7) of the 292 million
people living with chronic hepatitis B (CHB) worldwide (8).
Available data suggest that HBV–HDV coinfection is most preval-
ent in Central Asia, Eastern Europe, Central Latin America, and
West and Central Africa (5–7). People most at risk for HBV–HDV
coinfection are likely to be living in or have emigrated from these
regions, have a history of intravenous drug use, are men who have
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sex with men, have HIV or hepatitis C virus (HCV), or have mul-
tiple sex partners (9,10). The rates of coinfection with HDV range
from more than 10% to as high as 70% in countries in Africa,
Asia, and parts of South America (11). In industrialized countries,
such as Germany, England, and France, studies have shown re-
cent increases in HDV prevalence (12,13). Epidemiologic and
clinical research on HDV is sparse, contributing to an incomplete
understanding of the actual disease burden, low global testing
rates, and lack of effective treatments (12–14). Only people who
already have CHB, or people who contract HBV and HDV
through simultaneous exposure, can become infected (14), creat-
ing a defined risk group. Despite these factors, awareness among
patients and providers is low, and treatment of HDV is far behind
medical advancements for HBV and HCV (15,16).
No US Food and Drug Administration–approved treatment of
HDV exists,  and the only somewhat effective treatment is
pegylated interferon, with only 25% to 30% of patients able to
control the virus with weekly injections administered for at least 1
year (17,18). When coinfection is poorly controlled, patients are 3
times as likely to develop cirrhosis and liver cancer, compared
with HBV infection alone. Approximately 70% to 90% of coinfec-
ted patients develop cirrhosis within 5 to 10 years (19–22). Des-
pite its discovery more than 40 years ago, knowledge of HDV is
limited, and little is known about the informational needs and ex-
periences of people living with HDV.
Methods
We analyzed HDV-related email queries sent to the Hepatitis B
Foundation, a US-based nonprofit organization, from October
2016 through January 2019 to identify information gaps and un-
derstand the lived experience of patients with HDV. The non-
profit organization receives queries as part of a free helpline, a ser-
vice to provide information, resources, and support to people af-
fected by HBV–HDV coinfection. The helpline is run by trained
community health education specialists who are knowledgeable
about HBV and HBV–HDV coinfection, and it provides patients
with general guidance, disease information, and referrals to physi-
cians or other health care providers.
All HDV-related queries received over 28 months were collected
and de-identified by a trained researcher (S.P.). Queries that ini-
tially were not in English (n = 2) were translated using an online
translation tool. Codes were developed in 2 ways: a priori (in-
formed by the literature) and through line-by-line reading of a sub-
sample of queries. Each code was given an explicit definition to
ensure coding accuracy and improve intercoder reliability (23,24).
Coding was performed by using NVivo12 software (QRS Interna-
tional), and all data were independently coded by 2 members of
the research team (S.F., P.K.). Intercoder reliability was assessed
by using the κ coefficient to identify coding discrepancies. The
analysis team met (P.K., S.F., C.F., R.F.) throughout the coding
process to discuss and resolve coding discrepancies until an ac-
ceptable final κ was achieved. Three of 19 codes had a mean κ of
less than 0.75. These codes were examined in more detail by the
analysis team so that coding discrepancies could be resolved, and
κ scores were recalculated. This study was approved by the Heart-
land institutional review board and acknowledged by the Thomas
Jefferson University institutional review board.
Results
A total of 65 HDV-related queries were received from October
2016 to September 2019 and were included in this analysis. Most
queries were from Romania (n = 11, 16.9%), Pakistan (n =10,
15.4%), and the United States (n = 9, 13.8%) (Table). Just over
half of individuals identified themselves within the queries; of
these, 31% self-identified as living with HBV–HDV coinfection (n
= 20), and the remainder reported being caregivers, family, or
friends of those with HDV (n = 10, 15%) or providers (n = 4, 6%).
The mean adjusted final κ was 0.91 (range, 0.78–1.00), corres-
ponding to near perfect intercoder agreement. Thematic analysis
of queries identified 4 dominant themes, 3 related to a need for in-
formation about 1) the disease and its prevention, 2) disease symp-
toms and outcomes, and 3) treatment options.
Need for information on HDV diagnosis and
prevention
People living with HDV and their family, friends, and caregivers
often had questions about a new diagnosis of HDV, explicitly con-
veying questions about how to interpret diagnostic laboratory find-
ings. For instance, one individual was unsure whether HDV-
positive results meant a worsening or spread of an existing dis-
ease (HBV) or was a new infection. An example of this theme
came from the following query: “I tested positive for HBV in
2012, and all I was told is that it would clear. No medication was
prescribed. Yesterday I went for another test and was told that [it
is] HDV. . . I do not understand what this means. [Is] this a new
infection, or the disease is spreading?” After being diagnosed with
both HBV and HDV, one patient wondered why their hepatitis res-
ults had drastically changed, despite being on medications, and
asked for clarification of these results: “I have been on peg-
Interferon for 12 weeks and Baraclude for 1 year. Now my en-
zymes are sky high, but my HBsAg has dropped to 26,000. At the
same time, [my] HBV viral load has increased significantly. My
question is, why has my viral load increased?”
Individuals receiving an initial diagnosis of HDV tended to have
general questions about the disease. These questions asked either
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for advice on immediate next steps to take (eg, “What do I need to
do?”) or for clarification about an HDV diagnosis (eg, “What [is]
the meaning of delta virus?”) After receiving a diagnosis of HDV
from their physician, another patient was notified of the rarity of
the disease and re-emphasized the need for more information (eg,
“Do you know of people with both hep B and D [and basal core
mutation] or have any information on this?”) Patients and family
members of those with HDV also had concerns about disease
transmission. One query asked about how HDV was contracted in
order to avoid the disease. Other patients and family members had
questions about specific modes of disease transmission. For in-
stance, another individual, the fiancé of someone living with
HDV, had concerns about sexual transmission. This individual de-
scribed, “My fiancé has just been presently diagnosed with hepat-
itis D infection. Am I safe or at risk of infection after sex/intimacy
with him? Please, I need clarification.” Those living with HDV
and family members wanted additional information about how to
prevent HDV (“Please, how is hep D contracted and [what are]
ways to avoid contracting the virus?”) or expressed confusion
about an HBV–HDV diagnosis, despite taking preventive meas-
ures. “I kindly need [some] help to figure this [out,] as [I] am not
sure why [I] was negative . . . got the preventive shots and all of a
sudden now the results are showing positive as in having a chron-
ic hep B infection.” A pregnant woman worried about transmis-
sion to her newborn and asked for methods to prevent potential
harm from the disease for her child: “We’re expecting a baby in a
month’s time. What can I do to protect the baby?”
Understanding disease symptoms and outcomes
Patients with HDV described concerns about the risk of liver can-
cer or liver damage due to the disease. Sometimes patients asked
about mechanisms through which HDV increased liver damage
(eg, “I would like to know how hepatitis D [coinfection] comes
about increasing the severity of the liver condition”) or shared in-
formation about newly diagnosed liver damage that surprised
them. One participant stated, “I have what I’ve been told is a rare
situation. Early this year tests came back that I had cirrhosis and
another hepatitis, hep D (delta), along with the hep B, plus a basal
core mutation, making me at high risk for liver cancer.” Often, pa-
tients and family members were curious about specific symptoms
and wondered whether these could be attributed to HDV or other
causes. “I have chronic hepatitis B and also ‘have’ hepatitis D
(delta). I have multiple symptoms (abdominal pain, back pain,
nausea, etc) that may or may not be related to my hepatitis. . . .
We’ve been trying to determine the cause of my symptoms for
years, thus if you happen to have any information on the above or
are able to point me to where I can get more info, that would be
greatly appreciated.”
Treatment options
The need for clinical trials was the most salient aspect of “Treat-
ment Options” and represented 16.9% (n = 11) of all queries that
were included (N = 65). Patients and caregivers in many countries
wanted to know about the availability of clinical trials in their own
country and asked for information on how to register for and parti-
cipate in these trials. One individual asked, “Is there [an] open
phase 3 hepatitis delta clinical trial? Could you tell me how to re-
gister to participate?”
Patients also showed interest in finding curative treatments for
HDV, especially when faced with a new diagnosis of the disease.
“I have had hepatitis B for nearly 10 years and recently found out
that I also have hepatitis D. I can’t say I am feeling well. Isn’t
there any cure found for these?” Queries contained a variety of
questions on medication, including recommendations for the new-
est and best medications, medication availability in certain coun-
tries, and advice on current medication regimens. The following is
an excerpt from a query about the best medication recommenda-
tions after a patient was given a diagnosis of HDV.
“[Could] you please help me to find or recommend [to] me any
latest best medication for this diagnosis?” Patients and family
members of those with HDV were also very interested in treat-
ment options. Questions included whether there were any treat-
ments for HDV and what new treatments were available. “My
mom is suffering from Hepatitis Delta. Is there any treatment for
that virus?”
When faced with a new diagnosis of HDV, patients asked wheth-
er there were any lifestyle modifications they could make to im-
prove the quality of life with the disease or discussed lifestyle
modifications they had already implemented. These lifestyle modi-
fications were often made in conjunction with medications and in-
cluded eating healthy and abstaining from certain habits, such as
smoking and drinking. “Right now, I take only those medicines, I
try to eat healthy and I try to rest how much I can. I don’t drink al-
cohol and I don't smoke. Should I do other things?”
In addition to Western medicine or treatment modalities, some pa-
tients opted to try alternative therapies for their HBV–HDV,
which included herbal or plant-based supplements. Patients using
herbal or “natural” treatments often used these in conjunction with
Western medications and reported using herbal treatments after
they had tried other treatment options. “After I searched other
treatment for my diseases, I discovered a clinic with natural drugs:
SECOM. I was there and the doctor gave me a personal treatment.
After 2 months taking these, ALT has normal value and AST is
bigger with only 11 units.”
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Barriers to care and quality of life
Patients and caregivers or other family members sometimes noted
different barriers to adequate care, including poverty, access to
doctors or medication, or language barriers. Poverty was the most
commonly noted reason for requesting help and more information.
One individual described, “I need your help because [I] belong to
a [low-income] family.” People living with HDV and their family
members often felt worried, shocked, scared, and uncertain after
receiving a diagnosis of HDV. One person living with HDV was
very worried and expressed explicit concerns about how long they
could live with the disease, stating, “I just found out that I have
hepatitis B and D together. . . . How long can I live? What should I
do? [Please], help me! I’m so scared.”
Discussion
Qualitative analysis of queries received by the Hepatitis B Found-
ation indicated that people living with HDV and their family
members had considerable concerns and the need for information
that were related to 4 distinct thematic categories: 1) disease
knowledge and prevention, 2) disease symptoms and outcomes, 3)
treatment options, and 4) barriers and quality of life. People living
with HDV and their family members and friends requested in-
formation on treatment options, medication access, diagnostic test
interpretation, and availability of clinical trials. Questions about
the availability of clinical trials and how to register for such trials
was the most common topic among all queries.
To our knowledge, this study is the only one that qualitatively ex-
amines the experiences and needs of people living with HDV and
their family members to assess needs and barriers in this popula-
tion. Prior studies have used qualitative methods to explore vari-
ous HBV patient experiences, including initial responses to dis-
ease, stigma associated with the disease, stress and anxiety about
one’s health, and concerns about premature death (25–30), but to
our knowledge none have examined the impact of HBV–HDV
coinfection. This study showed similar sentiments and family
members expressed worry about loved ones with HDV, which of-
ten manifested in searches for treatment options. People who re-
ceived an initial diagnosis of HDV also expressed fear and anxi-
ety, which was reflected in concerns about lifespan with the dis-
ease and confusion about the diagnosis. Despite these similarities,
HDV patient experiences may be unique from those with HBV,
HCV, or both because of the rareness of the condition and a lack
of disease awareness among the general public. Future research
should examine the differences between HDV patient experiences
compared with HCV and HBV patient experiences.
Another notable commonality between this study’s findings and
those of others is the lack of disease knowledge and lack of know-
ledge of treatment and screening options for viral hepatitis
(27,29,31). People who sent queries about HDV had little know-
ledge of HDV but showed interest in furthering their knowledge,
especially with regard to treatments and clinical trial research.
These findings indicate the need for improved efforts to educate
people who are diagnosed with HDV about their disease with the
goal of increasing patient and caregiver knowledge. More know-
ledge about the disease among people living with HBV increases
patient acceptance of disease and self-efficacy in disease manage-
ment (29), which, based on our findings, could also be the case for
those living with HDV. Future research should explore the rela-
tionship between HDV disease knowledge and patient self-
efficacy in disease management.
Most qualitative literature about people living with viral hepatitis
focuses on varied aspects of HBV and HCV patient experiences,
in particular, the stigma associated with the disease, lack of dis-
ease knowledge, poor quality of life, and the complex emotions
associated with having the disease. None of the queries we ana-
lyzed contained questions or content that referred to stigma or dis-
crimination associated with HDV, possibly because patients had
more immediate concerns about managing their health condition.
No qualitative study has explored the needs and barriers of HDV
patients, who may face more urgent needs related to treating and
controlling disease progression (26,32), so more research is
needed to understand stigma in the context of HDV.
In our study, people affected by HDV needed information about
types of treatment options available to them, medication access,
diagnostic test interpretation, and availability and location of clin-
ical trials, the latter being the most common topic of all queries.
These questions suggest that individuals with HDV may have
challenges accessing medication, physicians with adequate know-
ledge about the disease, and clinical trials, and more work is
needed to fully understand these challenges. Our findings also
suggest that the subset of individuals who emailed queries spe-
cifically related to treatment may have already done online re-
search about HDV before sending an email query. For example,
many individuals who inquired about clinical trials mentioned
hepatitis-specific medications and prepared detailed questions
about interpretations of laboratory test results.
Results of this study emphasize the importance of targeted,
patient-centered education for patients with HDV, and future edu-
cation should focus on clarifying laboratory results, treatment op-
tions, medication access, and clinical trial resources for this popu-
lation. Given the complex set of emotional, medical, and lifestyle
factors that affect patients with HDV, materials should also be de-
livered accessibly and at the appropriate level of health literacy for
those affected. Globally, patients with HBV–HDV coinfection
may be more likely to be from more rural, isolated, or lower-
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income countries. Providers, especially those managing patients
with HBV–HDV coinfection (primarily hepatologists), and public
health professionals have a critical role in disseminating this in-
formation to patients because of their disease-specific knowledge
and areas of expertise.
Strengths and limitations
Our sample was people with HDV who sent email queries to a
nonprofit helpline, so it may not be representative of the larger
HDV-affected population. The queries analyzed in this study were
limited to those received by the Hepatitis B Foundation. Many
queries were from the United States, an industrialized country
with a known lower incidence of HDV but with higher awareness.
Because the Hepatitis B Foundation is US-based, Americans liv-
ing with HDV and their caregivers may be more familiar with the
foundation’s work and have more access to their resources, so our
results are subject to regional bias.
Our data consisted only of email queries and did not include other
forms of correspondence, such as in-person visits or queries re-
ceived via mail, telephone, or social media platforms, so our
sample may be less representative of the total population of pa-
tients with HDV. However, telephone calls to the Hepatitis B
Foundation, are not recorded, so the ability to obtain these data
was limited. Email queries were chosen for this analysis as the ini-
tial stage of this research. In the future, we hope to expand on this
research to explore queries sent via social media platforms, includ-
ing Instagram, Facebook, and Twitter. We expect that concerns
will be similar to those of people using email. The sole use of
email-based correspondence also may have affected sample rep-
resentativeness because it limits the sample to people who have
access to working internet (or electricity) and email accounts. Giv-
en the distribution of HDV in industrialized countries in Asia and
Africa, many HDV patients may tend to live in less resource-rich
environments. Our sample may not be representative of the larger
HDV-affected population.
Conclusion
This qualitative research indicated knowledge gaps among pa-
tients with HDV related to disease prevention, transmission risk to
close family members, disease symptoms and long-term outcomes,
and treatment options as well as barriers to care and overall qual-
ity of life. Our findings expand on the needs and barriers of indi-
viduals directly affected by HDV. A summary of these queries
will be shared with providers who treat patients with HDV to help
them expand their knowledge and understanding of the needs of
their patients and their caregivers, and the data will be used to cre-
ate more resources tailored to meet the unique needs of people liv-
ing with HDV. Our findings may also be used to better under-
stand the information needs, challenges, and quality of life implic-
ations of patients with HDV to inform clinical trial designs and the
development of new treatments. Like other chronic viral hepatitis
patients, those affected by HDV need more education on certain
aspects of their disease. Although our findings are not representat-
ive of the larger HDV global population, we believe that they sup-
port the claim of a larger knowledge gap that exists surrounding
HDV. Because people living with HDV and their family members
tended to need more information on treatment options, medication
access, diagnostic test interpretation, and clinical trials, providers
and public health organizations therefore have the most crucial
role in educating people with HDV and their families. Ultimately,
targeted education interventions for this patient population are im-
portant because they can improve self-efficacy in disease manage-
ment and overall quality of life. Future research is needed to fully
understand the impact HDV has on the lives of people who are af-
fected, and the knowledge gained from this research will help
guide future research projects and outreach initiatives for those af-
fected by HDV. We hope our findings can help educate providers,
public health professionals, and the pharmaceutical and biotechno-
logy industries on the needs of individuals living with HDV, so we
can collectively address them.
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Table
Table. Frequency of HDV-Related Queries (N = 65) to the Hepatitis B Foundationa, by Country (n = 17), 2016–2019
Country Query Frequency (%) (n = 65)
Romania 11 (16.9)
Pakistan 10 (15.4)















Abbreviation: HDV, hepatitis delta virus.
a The Hepatitis B Foundation is a US-based nonprofit organization.
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